ID   COR-L23/CPR
AC   CVCL_2007
SY   COR-L 23/CPR; L23/CPR
DR   CLO; CLO_0002583
DR   CLDB; cl5053
DR   ECACC; 96042336
DR   GEO; GSM827460
DR   LINCS_LDP; LCL-1779
DR   Wikidata; Q54814272
RX   PubMed=1327513;
RX   PubMed=20215515;
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Homozygous for KRAS p.Gly12Val (c.35G>T) (from parent cell line).
CC   Omics: SNP array analysis.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): ECACC
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,11
ST   D16S539: 11,13
ST   D5S818: 10,12
ST   D7S820: 9
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C4450; Large cell lung carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1139 ! COR-L23
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 17
//
RX   PubMed=1327513;
RA   Twentyman P.R., Wright K.A., Mistry P., Kelland L.R., Murrer B.A.;
RT   "Sensitivity to novel platinum compounds of panels of human lung
RT   cancer cell lines with acquired and inherent resistance to
RT   cisplatin.";
RL   Cancer Res. 52:5674-5680(1992).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//